Patents by Inventor Christoph Arth
Christoph Arth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190314294Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a nom-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: ApplicationFiled: May 23, 2019Publication date: October 17, 2019Applicants: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AGInventors: Hans-Michael WOLFF, Christoph ARTH, Luc QUERE, Walter MÜLLER
-
Patent number: 10350174Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: GrantFiled: May 17, 2018Date of Patent: July 16, 2019Assignees: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AGInventors: Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
-
Patent number: 10130589Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: GrantFiled: January 31, 2018Date of Patent: November 20, 2018Assignees: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AGInventors: Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
-
Publication number: 20180263921Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: ApplicationFiled: May 17, 2018Publication date: September 20, 2018Applicants: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AGInventors: Hans-Michael WOLFF, Christoph ARTH, Luc QUERE, Walter MÜLLER
-
Publication number: 20180147154Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: ApplicationFiled: January 31, 2018Publication date: May 31, 2018Applicants: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AGInventors: Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
-
Patent number: 9925150Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: GrantFiled: December 22, 2010Date of Patent: March 27, 2018Assignees: LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbHInventors: Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
-
Patent number: 9364541Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Type: GrantFiled: July 2, 2013Date of Patent: June 14, 2016Assignee: UCB PHARMA GMBHInventors: Hans-Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane
-
Publication number: 20130296423Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Type: ApplicationFiled: July 2, 2013Publication date: November 7, 2013Inventors: Hans-Jürgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
-
Patent number: 8501723Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Type: GrantFiled: January 22, 2010Date of Patent: August 6, 2013Assignee: UCB Pharma GmbHInventors: Hans-Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane, Kerstin Paulus, Meike Irngartinger, Hans Lindner
-
Publication number: 20120322845Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: ApplicationFiled: December 22, 2010Publication date: December 20, 2012Applicants: Lohmann Therapie-Systeme AG, UCB Pharma GmbHInventors: Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
-
Patent number: 8088398Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Type: GrantFiled: December 23, 2008Date of Patent: January 3, 2012Assignee: UCB Pharma GmbHInventors: Hans-Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane
-
Patent number: 7807715Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Type: GrantFiled: June 7, 2007Date of Patent: October 5, 2010Assignee: UCB Pharma GmbHInventors: Christoph Arth, Michael Komenda, Fatima Bicane, Hans-Jurgen Mika
-
Publication number: 20100130606Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Type: ApplicationFiled: January 22, 2010Publication date: May 27, 2010Applicant: SCHWARZ PHARMA AGInventors: Hans-Jürgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
-
Publication number: 20090117159Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Type: ApplicationFiled: December 23, 2008Publication date: May 7, 2009Applicant: SCHWARZ PHARMA AGInventors: Hans-Jurgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
-
Publication number: 20080138421Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Type: ApplicationFiled: June 7, 2007Publication date: June 12, 2008Inventors: Christoph Arth, Michael Komenda, Fatima Bicane, Kerstin Paulus, Meike Irngartinger, Hans Lindner
-
Patent number: 6783769Abstract: The invention relates to a transdermal therapeutic system (TTS) for transcutaneously administering tolterodine over a period of several days and to a method for producing the same. The TTS contains a self-adhesive layer-shaped matrix composition which contains a (meth)acrylate copolymer comprising ammonium groups. The TTS also contains at least one plasticizer and up to 25 wt, % of tolterodine.Type: GrantFiled: April 25, 2002Date of Patent: August 31, 2004Assignee: Schwarz Pharma AGInventors: Christoph Arth, Claus Meese, Dietrich Wilhelm Schacht, Hans-Michael Wolff
-
Patent number: 6562367Abstract: A transdermal therapeutic system for transcutaneous administration of sexual steroid hormones over long time periods, and a solvent-free method for the production thereof, is disclosed. The steroid hormones are subjected to as little thermal exposure as possible, thereby avoiding decomposition of the steroid hormones.Type: GrantFiled: March 16, 2000Date of Patent: May 13, 2003Assignee: Schwarz Pharma AGInventors: Hans-Michael Wolff, Christoph Arth
-
Patent number: 6555129Abstract: A transdermal therapeutic system (TTS) for transcutaneous administration of oxybutynin over a period of several days, in addition to a method for the production of the TTS without the use of solvents, are disclosed. The TTS contains a matrix mass containing oxybutynin in the form of a self-adhesive layer. The matrix mass includes ammonium-group-containing (meth)acrylic polymers, at least one citric acid ester, and 5-25 wt. % oxybutynin.Type: GrantFiled: October 26, 2000Date of Patent: April 29, 2003Assignee: Schwarz Pharma AGInventors: Christoph Arth, Andreas Kollmeyer-Seeger, Stephan Rimpler, Hans-Michael Wolff
-
Patent number: 6555131Abstract: A stable therapeutical transdermal system for the transcutaneous delivery of levonorgestrel, alone or together with other sex steroid hormones, over a long time period is disclosed. A method of producing the transdermal system that avoids the use of solvents and avoids degradation of the steroid hormones also is disclosed.Type: GrantFiled: March 9, 2000Date of Patent: April 29, 2003Assignee: Schwarz Pharma AGInventors: Hans-Michael Wolff, Christoph Arth
-
Patent number: 6461636Abstract: The invention relates to a transdermal therapeutic system (TTS) for the transcutaneous administration of pergolide over several days and to a method for its manufacture without using solvents. The TTS contains a matrix mass, containing pergolide and taking the form of a layer, which contains a (meth)acrylate copolymer containing ammonio groups or a mixture of a (meth)acrylate copolymer containing amino groups and a (meth)acrylate polymer containing carboxyl groups, 10-50% by weight propylene glycol and up to 5% by weight pergolide.Type: GrantFiled: October 10, 2000Date of Patent: October 8, 2002Assignee: Schwarz Pharma AGInventors: Christoph Arth, Andreas Kollmeyer-Seeger, Stephan Rimpler, Hans-Michael Wolff